Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.micpath.2020.104236 http://scihub22266oqcxt.onion/10.1016/j.micpath.2020.104236 32376359!7196559!32376359     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Microb+Pathog 2020 ; 145 (ä): 104236 Nephropedia Template TP {{tp|p=32376359|t=2020. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 |pdf=|usr=}}{{32376359}} gab.com Text Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 JO: Microb Pathog http://www.kidney.de/pget.php?&tw=1&pmid=32376359 #FOAvip Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. In the absence of any antiviral or immunomodulatory therapies, the disease is spreading at an alarming rate. A possibility of a resurgence of COVID-19 in places where lockdowns have already worked is also developing. Thus, for controlling COVID-19, vaccines may be a better option than drugs. An mRNA-based anti-COVID-19 candidate vaccine has entered a phase 1 clinical trial. However, its efficacy and potency have to be evaluated and validated. Since vaccines have high failure rates, as an alternative, we are presenting a new, designed multi-peptide subunit-based epitope vaccine against COVID-19. The recombinant vaccine construct comprises an adjuvant, cytotoxic T-lymphocyte (CTL), helper T-lymphocyte (HTL), and B-cell epitopes joined by linkers. The computational data suggest that the vaccine is non-toxic, non-allergenic, thermostable, with the capability to elicit a humoral and cell-mediated immune response. The stabilization of the vaccine construct is validated with molecular dynamics simulation studies. This unique vaccine is made up of 33 highly antigenic epitopes from three proteins that have a prominent role in host-receptor recognition, viral entry, and pathogenicity. We advocate this vaccine must be synthesized and tested urgently as a public health priority. Twit Text FOAVip Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 ????Microb Pathog http://www.kidney.de/pget.php?&tw=1&pmid=32376359 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32376359 #FOAvip English Wikipedia <ref>{{Cite pmid|32376359}}</ref> Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 #MMPMID32376359 Kalita P; Padhi AK; Zhang KYJ; Tripathi T Microb Pathog 2020[Aug]; 145 (ä): 104236 PMID32376359show ga Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. In the absence of any antiviral or immunomodulatory therapies, the disease is spreading at an alarming rate. A possibility of a resurgence of COVID-19 in places where lockdowns have already worked is also developing. Thus, for controlling COVID-19, vaccines may be a better option than drugs. An mRNA-based anti-COVID-19 candidate vaccine has entered a phase 1 clinical trial. However, its efficacy and potency have to be evaluated and validated. Since vaccines have high failure rates, as an alternative, we are presenting a new, designed multi-peptide subunit-based epitope vaccine against COVID-19. The recombinant vaccine construct comprises an adjuvant, cytotoxic T-lymphocyte (CTL), helper T-lymphocyte (HTL), and B-cell epitopes joined by linkers. The computational data suggest that the vaccine is non-toxic, non-allergenic, thermostable, with the capability to elicit a humoral and cell-mediated immune response. The stabilization of the vaccine construct is validated with molecular dynamics simulation studies. This unique vaccine is made up of 33 highly antigenic epitopes from three proteins that have a prominent role in host-receptor recognition, viral entry, and pathogenicity. We advocate this vaccine must be synthesized and tested urgently as a public health priority. |Antigens, Viral/immunology[MESH] |Betacoronavirus/*immunology[MESH] |COVID-19[MESH] |Coronavirus Infections/immunology/*prevention & control[MESH] |Epitopes, B-Lymphocyte/immunology[MESH] |Epitopes, T-Lymphocyte/immunology[MESH] |Humans[MESH] |Molecular Dynamics Simulation[MESH] |Nucleocapsid Proteins/*immunology[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/immunology/*prevention & control[MESH] |SARS-CoV-2[MESH] |Spike Glycoprotein, Coronavirus/*immunology[MESH] |Vaccines, Subunit/*immunology[MESH]Design of a peptide-based subunit vaccine against novel coronavirus SA(epmc).pdf DeepDyve Pubget Overpricing